[go: up one dir, main page]

DK406686D0 - Carboxylsyrederivater - Google Patents

Carboxylsyrederivater

Info

Publication number
DK406686D0
DK406686D0 DK406686A DK406686A DK406686D0 DK 406686 D0 DK406686 D0 DK 406686D0 DK 406686 A DK406686 A DK 406686A DK 406686 A DK406686 A DK 406686A DK 406686 D0 DK406686 D0 DK 406686D0
Authority
DK
Denmark
Prior art keywords
carboxylic acid
acid derivatives
derivatives
carboxylic
acid
Prior art date
Application number
DK406686A
Other languages
English (en)
Inventor
Hans Bundgaard
Niels Moerk Nielsen
Original Assignee
Hans Bundgaard
Niels Moerk Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hans Bundgaard, Niels Moerk Nielsen filed Critical Hans Bundgaard
Priority to DK406686A priority Critical patent/DK406686D0/da
Publication of DK406686D0 publication Critical patent/DK406686D0/da
Priority to AT87905946T priority patent/ATE75725T1/de
Priority to PCT/DK1987/000104 priority patent/WO1988001615A1/en
Priority to AU79602/87A priority patent/AU7960287A/en
Priority to JP62505328A priority patent/JPH01501310A/ja
Priority to US07/188,407 priority patent/US5073641A/en
Priority to DE8787905946T priority patent/DE3778873D1/de
Priority to EP87905946A priority patent/EP0278977B1/en
Priority to CA000545423A priority patent/CA1325422C/en
Priority to DK227088A priority patent/DK167007B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK406686A 1986-08-26 1986-08-26 Carboxylsyrederivater DK406686D0 (da)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK406686A DK406686D0 (da) 1986-08-26 1986-08-26 Carboxylsyrederivater
AT87905946T ATE75725T1 (de) 1986-08-26 1987-08-25 Derivate von vorstufen von carboxylsaeuremedikamenten.
PCT/DK1987/000104 WO1988001615A1 (en) 1986-08-26 1987-08-25 Prodrug derivatives of carboxylic acid drugs
AU79602/87A AU7960287A (en) 1986-08-26 1987-08-25 Prodrug derivatives of carboxylic acid drugs
JP62505328A JPH01501310A (ja) 1986-08-26 1987-08-25 カルボン酸薬物のプロドラッグ誘導体
US07/188,407 US5073641A (en) 1986-08-26 1987-08-25 Prodrug derivatives of carboxylic acid drugs
DE8787905946T DE3778873D1 (de) 1986-08-26 1987-08-25 Derivate von vorstufen von carboxylsaeure-medikamenten.
EP87905946A EP0278977B1 (en) 1986-08-26 1987-08-25 Prodrug derivatives of carboxylic acid drugs
CA000545423A CA1325422C (en) 1986-08-26 1987-08-26 Prodrug derivatives of carboxylic acid drugs
DK227088A DK167007B1 (da) 1986-08-26 1988-04-26 Prodrugderivater af carboxylsyre-laegemidler, en fremgangsmaade til fremstilling heraf samt et praeparat indeholdende disse derivater

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK406686A DK406686D0 (da) 1986-08-26 1986-08-26 Carboxylsyrederivater

Publications (1)

Publication Number Publication Date
DK406686D0 true DK406686D0 (da) 1986-08-26

Family

ID=8129825

Family Applications (1)

Application Number Title Priority Date Filing Date
DK406686A DK406686D0 (da) 1986-08-26 1986-08-26 Carboxylsyrederivater

Country Status (7)

Country Link
US (1) US5073641A (da)
EP (1) EP0278977B1 (da)
JP (1) JPH01501310A (da)
AU (1) AU7960287A (da)
CA (1) CA1325422C (da)
DK (1) DK406686D0 (da)
WO (1) WO1988001615A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380705A (zh) * 2022-01-11 2022-04-22 四川大学 一种利用模拟酪氨酸羟化酶制备的纳米酶仿生合成左旋多巴的方法

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
JPS6425782A (en) * 1987-03-27 1989-01-27 Yoshitomi Pharmaceutical Benzopyranopyridineacetic acid ester compound
DK24089D0 (da) * 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5637616A (en) * 1993-06-18 1997-06-10 Arcturus Pharmaceutical Corporation Method for treating diseases mediated by proteases
US5458883A (en) 1994-01-12 1995-10-17 Duke University Method of treating disorders of the eye
IT1274175B (it) * 1994-11-22 1997-07-15 Lab Alchemia Srl Procedimento per la preparazione di una combinazione chimica farmacologicamente attiva
DE19529604A1 (de) * 1995-08-11 1997-02-13 Bayer Ag Endoparasitizide Mittel auf Basis von Didepsipeptiden, neue Didepsipeptide und ein Verfahren zu ihrer Herstellung
US6071934A (en) * 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
IT1290447B1 (it) 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
US6501188B1 (en) * 1997-07-03 2002-12-31 Micron Technology, Inc. Method for improving a stepper signal in a planarized surface over alignment topography
US20020128301A1 (en) * 1998-02-13 2002-09-12 Medivir AB Non-nucleoside reverse transcriptase inhibitors
US8722668B2 (en) 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
WO2002078681A2 (en) 2001-04-02 2002-10-10 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
JP2005527505A (ja) * 2002-02-22 2005-09-15 ニュー リバー ファーマシューティカルズ インコーポレイテッド 薬物血清レベルの患者間変動性を低減するためのペプチド−薬物複合体の使用
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
IL163667A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
WO2003091243A1 (en) * 2002-04-26 2003-11-06 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
AU2003285200A1 (en) * 2002-11-09 2004-06-03 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
MXPA05006924A (es) * 2002-12-27 2005-12-12 Daiichi Seiyaku Co Composicion para blanquear la piel.
US20030187072A1 (en) * 2003-02-14 2003-10-02 Kapin Michael A. Method of treating angiogenesis-related disorders
DK1644019T4 (da) * 2003-05-29 2018-04-23 Shire Llc Amfetaminforbindelser, der er resistente over for misbrug
BRPI0414876A (pt) * 2003-09-30 2006-11-21 New River Pharmaceuticals Inc compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
US8157788B2 (en) * 2003-11-06 2012-04-17 Paolo L. Manfredi Multi-site drug delivery platform
MX339690B (es) 2004-06-04 2016-06-06 Xenoport Inc Profarmacos de levodopa y sus composiciones y usos.
US7323585B2 (en) 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
JP2008517941A (ja) * 2004-10-21 2008-05-29 デューク・ユニバーシティー 眼科用薬剤
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20070053984A1 (en) * 2005-03-03 2007-03-08 Monique Spann-Wade Topical gels compositions
WO2007047447A2 (en) * 2005-10-17 2007-04-26 Neurotherapeutics Pharma, Inc. Diuretic-like compound analogs useful for regulation of central nervous system disorders
NZ569485A (en) 2005-12-05 2011-06-30 Xenoport Inc Levodopa prodrug mesylate, compositions thereof, and uses thereof
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
CN101679219B (zh) * 2006-12-19 2014-08-13 港大科桥有限公司 合成离子通道
US7709527B2 (en) 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
US7829592B2 (en) 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
EP2749552B1 (en) 2007-04-17 2015-11-18 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
US8383865B2 (en) 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
TW200924747A (en) * 2007-09-07 2009-06-16 Xenoport Inc Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090082464A1 (en) * 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200932734A (en) * 2007-10-15 2009-08-01 Xenoport Inc Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US7745670B2 (en) * 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
BRPI0912326A2 (pt) 2008-05-20 2015-10-06 Neurogesx Inc análogos de acetaminofeno hidrossolúveis
WO2009143297A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Carbonate prodrugs and methods of using the same
US7985776B2 (en) 2008-06-27 2011-07-26 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
US8148414B2 (en) 2008-08-19 2012-04-03 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
EP2349973A2 (en) * 2008-10-20 2011-08-03 XenoPort, Inc. Methods of synthesizing a levodopa ester prodrug
US7723515B1 (en) * 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
WO2011143237A1 (en) * 2010-05-10 2011-11-17 Surmodics, Inc. Glycerol ester active agent delivery systems and methods
US9861727B2 (en) 2011-05-20 2018-01-09 Surmodics, Inc. Delivery of hydrophobic active agent particles
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US11246963B2 (en) 2012-11-05 2022-02-15 Surmodics, Inc. Compositions and methods for delivery of hydrophobic active agents
US9555119B2 (en) 2012-11-05 2017-01-31 Surmodics, Inc. Composition and method for delivery of hydrophobic active agents
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
PT2970101T (pt) 2013-03-14 2018-10-04 Alkermes Pharma Ireland Ltd Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2017180723A1 (en) 2016-04-12 2017-10-19 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
US10703723B2 (en) 2017-03-09 2020-07-07 Truly Translational Sweden Ab Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
JP7197880B2 (ja) * 2017-10-19 2022-12-28 学校法人 名城大学 エステル化剤及びその利用
JP2022517743A (ja) * 2018-12-29 2022-03-10 ジャン，ジン アセチルサリチル酸誘導体およびその使用
US12226552B2 (en) 2019-09-30 2025-02-18 Surmodics, Inc. Active agent depots formed in situ
GB202111866D0 (en) 2021-08-18 2021-09-29 Ucl Business Plc Prodrugs for use in the treatment of tissue damage
CN117843589A (zh) * 2022-10-09 2024-04-09 天津谷堆生物医药科技有限公司 取代3-氟苯丙酸酯类化合物及其制备方法、药物组合及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE734487A (da) * 1968-07-11 1969-12-12
US4235887A (en) * 1977-04-13 1980-11-25 The Upjohn Company Process for therapeutic treatment
US4206220A (en) * 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents
US4363817A (en) * 1981-08-27 1982-12-14 Miles Laboratories, Inc. Enol acylate analogs of E1 and E2 prostaglandins
FR2514355A1 (fr) * 1981-10-14 1983-04-15 Fabre Sa Pierre Derives de biphenyl alcoyl carboxylates, leur procede de preparation et leur utilisation comme medicaments
AU557083B2 (en) * 1982-09-17 1986-12-04 Hans Bundgaard Pilocarpine prodrugs
US4588525A (en) * 1984-02-27 1986-05-13 Molecular Biosystems, Inc. Prodrug compounds for dermal application
FI860471A7 (fi) * 1984-06-08 1986-07-31 Ciba Geigy Ag N-substituoidut butyyriamidi -johdannaiset.
DE3517535A1 (de) * 1985-05-15 1986-11-20 Bayer Ag, 5090 Leverkusen 1-aryl-4-chinolon-3-carbonsaeuren
DE3542002A1 (de) * 1985-11-28 1987-06-04 Bayer Ag 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
DE3769676D1 (de) * 1986-03-14 1991-06-06 Fujisawa Pharmaceutical Co Prodrugverbindungen, verfahren zu deren herstellung und diese enthaltende zubereitungen mit verzoegerter freisetzung.
US4678806A (en) * 1986-09-02 1987-07-07 Merck & Co., Inc. Prodrugs of antihypercholesterolemic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380705A (zh) * 2022-01-11 2022-04-22 四川大学 一种利用模拟酪氨酸羟化酶制备的纳米酶仿生合成左旋多巴的方法

Also Published As

Publication number Publication date
EP0278977A1 (en) 1988-08-24
US5073641A (en) 1991-12-17
CA1325422C (en) 1993-12-21
JPH01501310A (ja) 1989-05-11
WO1988001615A1 (en) 1988-03-10
EP0278977B1 (en) 1992-05-06
AU7960287A (en) 1988-03-24

Similar Documents

Publication Publication Date Title
DK406686D0 (da) Carboxylsyrederivater
FI875484A7 (fi) Fosfinsyraderivat.
FI881501A7 (fi) 5-substituerade kinolon- och naftyridonkarboxylsyraderivat.
FI895718A7 (fi) -amino-boronihappo-johdannaiset
FI893592A7 (fi) Indazol-3 -karboxylsyraderivat.
DK686487D0 (da) 1h-imidazol-5-carboxylsyrederivater
DK259386A (da) Thiazolidincarboxylsyrederivater
IT1205123B (it) Acidi bifenil-idrossamici
DE3872937D1 (de) Benzoylaminophenoxybuttersaeure-derivate.
DK101287D0 (da) 1h-imidazol-5-carboxylsyrederivater
DE68913137D1 (de) Carbonsäure-Derivate.
DK655487D0 (da) Furanuronsyrederivater
DK549888D0 (da) Catechol-carboxylsyrederivater
GB8630759D0 (en) Carboxylic acid derivatives
FI906104A7 (fi) Naftyylisulfonyylialkaanihappojohdannaisia
DK670589D0 (da) Carboxylsyrederivater
DK426288A (da) Naphthalenpropionsyrederivater
DK718488A (da) Hydrogenerede 1-benzooxacycloalkylpyridincarboxylsyreforbindelser
DE3768557D1 (de) Trans-hexahydroterephthalsaeureesterderivate.
FI885053A7 (fi) Fluorerade arakidonsyraderivat.
DK317985A (da) Aminoeburnancarboxylsyrederivater
DK428087D0 (da) Dihydropyridin-5-phosphonsyre-cyclopropylenester
FI862965A7 (fi) Foerfarande foer framstaellning av kef-3-em-4-karboxylsyraderivat.
DK318085A (da) Nitroapovincaminsyrederivater
DK527486D0 (da) Substituerede 1-amino-cyclopropancarboxylsyrederivater

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment